FOXP3 and ataxia telangiectasia: Of note, using a blocking anti-VCAM-I antibody both during the phase of disease progression and during early clinical remission showed no significant effect on the clinical course of AT-EAE (Figure S1) and no marked changes in whole brain FACS analysis of CD4 and FoxP3 cell populations.